Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

10/10/2008 Record of Telecon


Submission Type: Original Application Submission ID: 125280/0 Office: OVRR

Japanese Encephalitis Virus Vaccine Inactivated

Intercell AG

Telecon Date/Time: 10-OCT-2008                          Initiated by FDA? Yes
Telephone Number:

Communication Categorie(s): Advice


Telecon Summary: Discussion of responses to CR letter. Responses have been accepted by product reviewers including proposed -(b)(4)- assay and validation. Sponsor agreed to provide specifications for protamine sulphate.

FDA Participants:

Daryll Miller
Richard Daemer
Lew Markoff
Li Yu
Barry Falgout
Destry Sillivan

Non-FDA Participants:

Thomas LINGELBACH, COO, Intercell AG
David VENABLES; Site Director, Intercell Biomedical
Christoph KLADE; Technology Development / Clinical Immunology
Murray MCKAY, Quality Operations
Fraser LESLIE; Quality and Regulatory Compliance
Paul WILSON, Intercell USA

Trans-BLA Group: No

Related STNs: None

Related PMCs: None

Return to Approval History, Letters, Reviews, and Related Documents

Page Last Updated: 06/17/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English